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ELISAMembranous nephropathy (MN) accounts for most cases of the nephrotic syndrome in adults. Recently, studies
on the underlying pathomechanisms led to the identiﬁcation of the podocyte M-type receptor for secretory
phospholipase A2 (PLA2R1) as a target antigen of circulating autoantibodies.
Autoantibodies to PLA2R1may not only play a role in the development of primaryMN, but also serve as amarker
for diagnosis, disease activity and therapy monitoring. Antibody detection is crucial to discriminate between
patients with primary MN and those with a secondary form of the disease, as both forms require different
diagnostic approaches and treatment strategies. Standardized test systems based on recombinant PLA2R1
allow for the sensitive and speciﬁc analysis of anti-PLA2R1 autoantibodies. Further research into pathogenic
mechanisms and other disease markers can pave the way for improved patient care.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.Contents1. Introduction: membranous nephropathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
1.1. Classiﬁcation and clinical presentation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
1.2. History . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
2. Autoimmune background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
2.1. Heymann nephritis: podocyte antigens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
2.2. Alloimmune neonatal membranous nephropathy: neutral endopeptidase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
2.3. Major target antigen: phospholipase A2 receptor 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
2.4. Other autoantigens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
3. Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
4. Serological diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
5. Anti-PLA2R1 autoantibodies as a marker for diagnosis and monitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
5.1. Differential diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
5.2. Disease activity and course . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
5.3. Therapy monitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
5.4. Risk estimation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
6. Outlook . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
Take-home messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112: +49 451 5855 591.
Schlumberger).
. Open access under CC BY-NC-ND license.
109W. Schlumberger et al. / Autoimmunity Reviews 13 (2014) 108–1131. Introduction: membranous nephropathy
1.1. Classiﬁcation and clinical presentation
Membranous nephropathy (MN) belongs to a family of kidney
diseases that is associated with inﬂammation and hypersensitivity of
the glomeruli (glomerulitis) and/or interstitium (nephritis) of the
kidney. This is in contrast to tubulopathies, where mainly the renal tu-
bules are affected. The characteristic hallmark of MN is a subepithelial
in situ deposition of immune complexes at the glomerular basement
membrane (GBM) [1]. Since the thickened GBM can be seen by light
microscopy in later stages of illness, this disease was initially termed
“membranous glomerulonephritis” [2].
Due to the formation of the immune deposits, the permeability of
the capillary loops is altered, thus leading to proteinuria and frequently
to a nephrotic syndrome. The latter is mainly characterized by protein-
uria (N3.5 g of protein in 24 h urine), hypoalbuminemia (b3 g/dl), hy-
perlipidemia and edema [3]. Accounting for about 20% of cases, MN
represents one of the most common causes of nephrotic syndrome [1].
Although spontaneous remission occurs in approximately one-third of
MN patients, a similar amount of patients develops end-stage renal fail-
ure within ten years [4]. The remaining third of the patients present
with a persistent proteinuria. The reported annual incidence of MN
amounts to 5–10 cases per million population in northern Europe [5].
Approximately, 20–30% of MN arises as a consequence of different
diseases or drug intoxication and are classiﬁed as ‘secondary’ MN.
They have to be differentiated from ‘primary’ MN (pMN), for which an
underlying secondary disease is unknown. pMN can be further sub-
divided into cases positive for autoantibodies to phospholipase A2
receptor 1 (anti-PLA2R1) and ‘idiopathic’ cases (without detectable
antibodies and not connected to another disease as mentioned above)
(Table 1) [6].
This discrimination is of great clinical importance as diagnostic pro-
cedures and therapeutic strategies completely differ between both
forms of the disease [7]. While in the secondary MN therapy focuses
on the underlying disease, patients with pMN are mostly treated with
an immunosuppressive strategy. Thus, the correct diagnosis avoids
unnecessary drug exposure or extensive diagnostic procedures.
1.2. History
The term ‘membranous glomerulonephritis’ (MGN)was coined by E.
Bell in 1946 [8]. By that time, it was not an independent disease but
rather belonged to a family of kidney diseases called Bright's disease
Type II, along with other conditions such as membranoproliferative
glomerulonephritis, minimal change disease and focal/segmental
glomerulosclerosis. In 1957, D. Jones described MGN as a distinct clini-
copathologic entity [9]. He established a special stain with periodic
acid-Schiff–silver methenamine (Jones' stain) and was able to show
(i) alterations in the basement membrane structure and (ii) thickening
of the capillary wall. Subsequently, Mellors et al. identiﬁed the thicken-
ing to be caused by (iii) subepithelially located electron-dense deposits,Table 1
Causes of membranous nephropathy.
Primary membranous nephropathy
– Anti-PLA2R1 autoantibodies
– Idiopathic (no detectable autoantibodies or not yet identiﬁed secondary cause)
Secondary membranous nephropathy (for a complete list see KDIGO [7])
– Infection-associated (e.g. hepatitis B virus, hepatitis C virus, syphilis, malaria)
– Disease-associated (e.g. rheumatoid arthritis, Sjögren's syndrome, bullous
pemphigoid)
– Drug/toxin-induced (e.g. nonsteroidal anti-inﬂammatory drugs, gold, mercury,
penicillamine)
– Malignancy-associated (carcinomas and non-carcinomas)
– Miscellaneous (e.g. sickle cell disease, Guillain-Barre syndrome)
KDIGO: “Kidney Disease: Improving Global Outcome”.containing immunoglobulin G (IgG) [10]. These three features are still
the hallmarks of MN histology.
2. Autoimmune background
2.1. Heymann nephritis: podocyte antigens
In 1959,W. Heymann developed a ratmodel that mimics the patho-
genic features of anMN (active Heymann nephritis) by immunizing rats
with a crude kidney extract plus complete Freund's adjuvant [11]. The
subepithelial deposits were induced by fractions of renal brush-border
membrane rather than by glomerular extracts. Therefore, it was be-
lieved that the deposits were circulating immune complexes consisting
of brush-border-related antigens and their corresponding antibodies
which were trapped in the glomeruli [1].
This initial assumption was disproved by the introduction of a pas-
sive model in the 1980s. By injecting anti-brush-border antibodies
into rats, immune deposits occurred in the glomeruli within minutes,
leading to proteinuria four to seven days later [12,13]. Additionally, ex-
periments based on in vitro and ex vivoperfused kidney systems showed
that the antibodies bound to a target antigen located on podocytes, thus
indicating an in situ formation of the immune complexes [12–14].
The primary autoantigen in both active and passive Heymann ne-
phritis was ﬁnally identiﬁed as the transmembrane protein megalin
(also known as low-density lipoprotein (LDL) receptor-related protein
2, LRP-2). Megalin is a 600 kDa endocytic receptor of the LDL receptor
family, that is localized within clathrin-coated pits in the brush-border
of proximal tubules and at the base and the sides of podocyte foot pro-
cesses [15–17].
Although the rat model of Heymann nephritis has added a major
contribution to our current understanding of the pathomechanisms in
MN, there is no evidence that megalin, which also occurs in humans,
is involved in the human disease as well.
2.2. Alloimmune neonatal membranous nephropathy: neutral endopeptidase
In 2002, the group of P. Ronco was the ﬁrst to describe a human
counterpart to passive Heymann nephritis in a case of neonatal MN,
which was associated with antibodies to neutral endopeptidase (NEP)
[18,19].
Here, a mother congenitally deﬁcient for NEP developed IgG1 and
IgG4 antibodies, when the antigen was expressed by the fetus. As the
antibodies are able to permeate through the placenta, they can bind to
native NEP of the fetus, thus leading to an MN at birth or at a later
time point. Based on these experiments, Kerjaschki postulated that (i)
there is a pivotal role for podocytes and theirmembrane-associated pro-
teins as targets for circulating antibodies aswell as deposit-formation and
that (ii) there is a common pathogenic pathway of glomerular immune-
complex diseases caused by complement activation [20].
2.3. Major target antigen: phospholipase A2 receptor 1
For many years the search for a target antigen in human MN had
been unsuccessful, since it was impossible to identify anti-podocyte an-
tibodies in the blood, podocyte antigens in immune deposits and specif-
ic reactivity in eluates from the kidneys of patients with MN [1]. This
was most likely due to the low titers of circulating antibodies that re-
quire highly sensitive detection methods. In 2009, Beck and coworkers
solved the problem by using a Western blot based on a glycoprotein-
enriched glomerular extract as the source of antigen [21]. The Western
blot was performed under non-reducing conditions and enabled the
identiﬁcation of a 185 kDa protein in 70% of serum samples from pa-
tients with primary, but not with secondary forms of MN. Reactivity to
this protein persisted after N-deglycosylation resulting in a 145 kDa
band, but disappeared after the use of reducing agents, suggesting that
the conformation of one or more epitopes in the molecule was
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phospholipase A2 receptor 1 (PLA2R1), was subsequently identiﬁed
viamass spectrometry of the reactive Western blot band.
PLA2R1 is a type 1 transmembrane receptor that is expressed by
podocytes. Besides a short membrane-spanning intracellular domain,
the receptor consists of a long extracellular domain with a cysteine-
rich head, a ﬁbronectin type II-like repeat domain and eight repeated
carbohydrate-recognition domains [22].
PLA2R1 is one of four members of the mannose receptor family [23].
All of themhave a conserved domain structure and share common char-
acteristics such as constitutive endocytic recycling at the plasma mem-
brane [24] whichmay provide a constant source of accessible PLA2R1 at
the podocyte membrane for immune-complex formation [23]. Further-
more, the receptors exist in both an extended and a bent conformation
conferring distinct ligand binding and oligomerization capacities [25].
Since the anti-PLA2R1 autoantibodies in patients with pMN only recog-
nize a conformation-dependent target epitope [21], it is assumed that
autoantibody-binding might only occur in one of these two conﬁgura-
tions. Therefore, pMNmight represent an autoimmune conformational
disease (‘conformeropathy’), such as Goodpasture syndrome [1]. The
biological function of PLA2R1 in podocytes is currently unknown.
2.4. Other autoantigens
In 2010, M. Prunotto et al. analyzed serum and glomeruli of patients
suffering from pMN [26]. With different proteomic methods they iden-
tiﬁed speciﬁc autoantibodies to superoxide dismutase 2 (SOD2) and al-
dose reductase (AR). These two antigens are, unlike NEP and PLA2R1,
cytosolic proteins that are generally not expressed on podocyte mem-
branes. It is postulated that translocation of the proteins to the podocyte
surface upon oxidative stress might play a role for the exposition of im-
munogenic epitopes [27]. Both antibody-speciﬁcities are not exclusive
for MN, and are only seen in 28–50% (SOD2) and 25–34% (AR) of the
cases [28,29]. Additionally, the group of G.M. Ghiggeri discovered anti-
bodies against α-enolase as a potential marker for pMN [30], but this
protein has been reported as a target of autoantibodies in other diseases
as well [31]. Besides cDNA screens which delivered potential hits [32],
more than 20 targets have been found in mice models of Heymann ne-
phritis which are still under investigation [33,34]. Hence, the quest for
new anti-podocytic antibodies is ongoing.
3. Pathogenesis
Although the exactmechanisms causing pMN are still under investi-
gation, different studies show a strong relationship between antibody
levels to podocytic proteins and disease activity. Since the discovery of
anti-PLA2R1 autoantibodies by Beck et al. in 2009, there has been strong
evidence that they are a key player in the pathogenesis [21]. For exam-
ple, autoantibodies to PLA2R1 can not only be eluted from kidney tissue
of pMN patients, but also colocalize with PLA2R1 in the glomeruli [21].
Therefore, it is widely accepted that upon binding of circulating autoan-
tibodies to PLA2R1 on podocytes, subepithelial deposits are formed in
situ, leading to complement activation and a cascade of events subse-
quent to the nephrotic syndrome (in most of the cases) [37]. Interest-
ingly, autoantibodies to PLA2R1 have shown to be mainly of the IgG4
subclass, which is regarded as being unable to activate the complement
pathway [38,39]. Nevertheless, since the terminal complement compo-
nent C5b-9 is detectable in glomeruli and urine of pMN patients [40,41],
there is strong evidence for the involvement of the complement system.
As most patients with MN have low or undetectable levels of C1q, the
classical complement pathway can be excluded. Therefore, either the al-
ternative or the lectin pathway seems to be predominantly involved
[42]. This hypothesis is supported by the notion, that mannose-
binding lectin can be detected in glomeruli of MN patients [43].
Despite the efforts so far, the etiology that leads to the described
pathogenesis is still unclear. It is assumed that podocyte injury, aconformational change in PLA2R1 induced by unknown factors or mo-
lecular mimicry by exogenous antigens could be involved [1]. Further-
more, stimulation of the relevant autoreactive B-cell clones as well as
B cell epitope spreading might contribute to the pathogenic condition.
4. Serological diagnosis
In order to use anti-PLA2R1 autoantibodies for the diagnosis, classiﬁ-
cation andmonitoring of pMN, validated test systemswith high sensitiv-
ity and speciﬁcity are necessary. Initially, Beck and coworkers detected
anti-PLA2R1 autoantibodies by applying a Western blot after non-
reducing SDS-PAGE [21]. However, this method is not suitable for most
diagnostic laboratories and for the analysis of large sample numbers. In
order to overcome these limitations, a recombinant cell-based indirect
immunoﬂuorescence assay (RC-IFA) has been developed that uses the
human cell line HEK293 overexpressing the full-length human PLA2R1
as substrate [44]. The PLA2R1-positive cells are arranged in a Biochip-
format in conjunctionwith “mock”-transfectedHEK293 cells in one incu-
bation ﬁeld (Fig. 1) [45]. Using this assay, antibodies to PLA2R1 could be
detected with maximal speciﬁcity (100%) and with a prevalence of 52%
in a cohort of pMNpatients, several of whichwere undergoing immuno-
suppressive therapy (Rituximab) [44]. This RC-IFA mosaic enables the
determination of anti-PLA2R1 autoantibody titers during the monitoring
of patients. For amore precise determination of antibody concentrations
(U/ml), Hofstra et al. introduced an in-house enzyme-linked immuno-
sorbent assay (ELISA), based on a recombinantly produced extracellular
domain of PLA2R1 as the solid surface [46]. Almost in parallel, a standard-
ized, commercially available ELISAwas developed using the same princi-
ple [47]. In a large cohort of clinically well-characterized patients with
primary or secondary MN, this ELISA revealed a very high sensitivity
with respect to RC-IFA (96.5%) at a set speciﬁcity of 99.9% [47]. Accord-
ingly, this assay provides a very accurate and quantitative method for
the assessment of anti-PLA2R1 autoantibodies that is highly suitable for
routine diagnostic purposes.
5. Anti-PLA2R1 autoantibodies as a marker for diagnosis
and monitoring
5.1. Differential diagnosis
In several studies anti-PLA2R1 autoantibodies have shown to be a
pathognomonic marker for pMN (Table 2). Initially, Beck et al. could
demonstrate that these autoantibodies were exclusively found in pa-
tients with pMN (70%), but not in secondary forms of the disease [21].
Furthermore, Gunnarsson and coworkers could also conﬁrm the
absence of anti-PLA2R1 autoantibodies in a European cohort of SLE
patients suffering from membranous lupus nephritis [48].
In a recent study, however, one of 20 Chinese patients withmembra-
nous lupus nephritis as well as a minor number of patients with MN
secondary to hepatitis B or cancer was anti-PLA2R1 positive [49].
Hence, the occurrence of anti-PLA2R1 autoantibodies in secondary
formsofMN is assumed to be either sporadic, based on ethnic differences
or due to a coincidental parallel presence of pMN. Therefore, it should not
be excluded that anti-PLA2R1 autoantibodies are present in a few cases of
MN deemed secondary because of a known other disease.
5.2. Disease activity and course
Anti-PLA2R1 autoantibodies are not only a speciﬁc marker for the
differential diagnosis of MN but also for its immunologic activity, as
shown by several independent groups [36,50,51]. According to the stud-
ies by Hofstra et al. the levels of circulating autoantibodies to PLA2R1
strongly correlated (73%) with the clinical disease activity, as measured
by level of proteinuria [36]. Furthermore, anti-PLA2R1 autoantibodies
are a good marker for predicting the course of the disease. In a group
of 90 patients with biopsy-proven MN and 90-month follow-up a
Fig. 1.Recombinant cell-based indirect immunoﬂuorescence assay (RC-IFA) for the determination of autoantibodies to PLA2R1. (A)Microscope slidewith ten reaction ﬁelds, each contain-
ing two Biochips with PLA2R1- or “mock”-transfected HEK293 cells forming a mosaic. (B) PLA2R1–RC-IFA after incubation with an anti-PLA2R1 positive serum.
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clinical outcome [51]. Moreover, Hofstra and coworkers reported that
renal failure tended to occur less frequently at low titers, whereas,
more importantly and statistically signiﬁcant, spontaneous remissions
were associated very rarely with high anti-PLA2R1 titers [46]. In the
same study, patients with high antibody titers required an immunosup-
pressive therapy more often than those presenting with low titers.Table 2
Prevalence of anti-PLA2R1 autoantibodies inmembranous nephropathy (modiﬁed and up-
dated from Hofstra [57]).
Author (year) Patients (n) Anti-PLA2R1 positive (n; %) Assay
Beck (2009) [21] 37 26 (70) WB
Kanigicherla (2011) 40 29 (73) ELISA
Debiec (2011) [58] 42 24 (57) IFA
Hoxha (2011) [44] 100 52 (52) IFA⁎
Beck (2011) [35] 14 12 (86) WB
Beck (2011) 35 25 (71) WB
Bruschi (2011) [30] 24 14 (58) WB
Hofstra (2011) [36] 18 14 (78) WB
Qin (2011) [49] 60 49 (82) WB
Hofstra (2012) [46] 117 79 (74) ELISA/IFA
Hoxha (2012) [50] 88 61 (69) IFA⁎
Behnert (2013) [59] 165 85 (52) ELISA/IFA⁎
Kanigicherla (2013) [51] 40 30 (75) ELISA
Cossey (2013) [60] 22 10 (45) IFA
Larsen (2013) [61] 85 64 (75) IFA
Svobodova (2013) [62] 65 45 (69) IFA⁎
ELISA: enzyme-linked immunosorbent assay; IFA: immunoﬂuorescence assay;WB:Western
blot.
⁎ Standardized method.Additionally, antibody levels allowed predictions concerning the re-
sponse to immunosuppressive therapy, deﬁned as time from the start
of therapy until remission [46]. A median of ﬁve, seven or ten months
was observed for low, medium or high classiﬁed anti-PLA2R1 titers,
respectively.
5.3. Therapy monitoring
Several studies provided evidence that patients undergoing immu-
nosuppressive therapy show a decline of anti-PLA2R1 titers, and that
the autoantibodies reappear during a relapse [35,44,52]. Characteristi-
cally, an increase in the antibody titers preceded a rise in proteinuria,
while a decrease in antibody levels was followed by a fall in proteinuria
[52]. According to Beck and Salant, residual proteinuria (2–3 g/24 h
urine) can still be detected at a point, where autoantibody levels already
reached zero [2]. They observed that, in patients with complete remis-
sion in response to immunosuppressive therapy, anti-PLA2R1 titers
become undetectable months before the proteinuria is completely re-
solved. Based on the correlation between clinical and immunological
disease activity, anti-PLA2R1 titers can be used for therapy monitoring
in patients with pMN, thus facilitating an early decision concerning
the choice of therapeutic strategies according to the “Kidney Disease:
Improving Global Outcome” (KDIGO) glomerulonephritis work group
[2,7,51,53].
5.4. Risk estimation
In up to 40% of patients, pMN recurs after renal transplantation [54].
The risk for recurrence is higher, when anti-PLA2R1 autoantibodies are
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PLA2R1 titers can be used to estimate, if or to which extent an immuno-
suppressive therapy after kidney transplantation is mandatory in order
to prevent a recurrence of MN. Two studies analyzed the role of anti-
PLA2R1 autoantibodies in kidney transplantation and in the differentia-
tion of recurrent versus de novoMN [55,56]. In the study of Debiec et al.
ﬁve out of ten patients with recurrent pMN were anti-PLA2R1 positive
while all de novo caseswere negative [55]. In addition, Larsen andWalk-
er reported that autoantibodies to PLA2R1 could be detected in 83% of
recurrent cases whereas only one de novo case (8%) was anti-PLA2R1
positive [56]. Thus, anti-PLA2R1 autoantibodies seem to play a pivotal
role in the recurrence of MN after transplantation, but not in the mech-
anisms resulting in de novoMN.
6. Outlook
The exact pathomechanisms leading to pMN are still widely un-
known. However, the identiﬁcation of anti-PLA2R1 autoantibodies by
Beck et al. in 2009 [21] evidenced an association between these autoan-
tibodies and disease pathogenesis. Since then, MN diagnosis, prognosis
and therapy decisions have changed. Today, anti-PLA2R1 autoantibodies
are accepted as a pathognomonic marker for pMN, thus enabling a dif-
ferential diagnosis of the disease. In addition, the antibody titers have
a highly predictive value concerningdisease activity and course, therapy
monitoring and risk estimation. Hence, anti-PLA2R1 autoantibodies ap-
pear as a promising and adequate theranostic marker for pMN as well.
Nevertheless, the prevalence of anti-PLA2R1 autoantibodies in pa-
tients with pMN differs between cohorts depending on immunosup-
pressive therapy, time intervals between biopsy and serum sampling,
and the usage of non-standardized test systems. Additionally, it should
be kept in mind that one-third of pMN patients undergo spontaneous
remission, accompanied by a decrease in autoantibodies to a level,
which might not be detectable anymore. In order to obtain reliable
prevalence data, prospective studies with large cohorts of patients are
needed. Moreover, the usage of standardized assays is highly recom-
mended. Recently, two standardized test systems (a recombinant cell-
based indirect immunoﬂuorescence assay and an ELISA) have been de-
veloped and proved highly speciﬁc for pMN. As supposed by the KDIGO,
further research should determine the potential role of additional bio-
markers [7]. These frame conditions can help tomark a new route to di-
agnosis and treatment of pMN.
Take-home messages
• The identiﬁcation of anti-PLA2R1 in patients with primary membra-
nous nephropathy (pMN) evidenced an association between organ-
speciﬁc autoantibodies and the pathogenesis of the disease.
• Anti-PLA2R1 is a pathognomonicmarker for pMNand enables a differ-
ential diagnosis of the disease. Besides predictions regarding disease
activity and course, the antibody titers allow for therapy monitoring
as well as estimations concerning the risk of recurrence after trans-
plantation. Therefore, anti-PLA2R1 has a promising theranostic value.
• Standardized test systems (recombinant cell-based indirect immuno-
ﬂuorescence assay and ELISA) allow for the quantiﬁcation of anti-
PLA2R1 autoantibodies, hence leading to a change in MN diagnosis,
prognosis and therapy decision.
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